cas 2940958-65-4|| where to buy 1-(4-bromo-2-methoxy-6-methyl-phenyl)-3-(2-trimethylsilylethoxymethyl)hexahydropyrimidine-2,4-dione

Product Name:1-(4-bromo-2-methoxy-6-methyl-phenyl)-3-(2-trimethylsilylethoxymethyl)hexahydropyrimidine-2,4-dione

IUPAC Name:1-(4-bromo-2-methoxy-6-methylphenyl)-3-{[2-(trimethylsilyl)ethoxy]methyl}-1,3-diazinane-2,4-dione

: CAS：2940958-65-4; Molecular Formula：C18H27BrN2O4Si; Purity：95%

Packing Unit	Available Stock	Price($)
CM1076998-100mg	in stock	ƏƩǠ
CM1076998-250mg	in stock	ƅȋǠ
CM1076998-500mg	in stock	ȋǠş
CM1076998-1g	in stock	ƻƻǠǺ

For R&D use only.

Inquiry Form

Chemical Name

CAS Number

Quantity*

Required Specifications*
(Assay %, Material Grade etc.)

Contact Name*

Contact Email*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 2940958-65-4 regularly via the above email.

Additional Notes

Verification code*

refresh

: CAS NO:2940958-65-4; Molecular Formula:C18H27BrN2O4Si; Melting Point:-; Smiles Code:COC1=CC(Br)=CC(C)=C1N1CCC(=O)N(COCC[Si](C)(C)C)C1=O; Density:

: Catalog Number:CM1076998; Molecular Weight:443.41; Boiling Point:; MDL No:; Storage:

: PROTAC-E3 Ligase Ligands; Bifunctional degrader molecules, also called proteolysis-targeting chimeras (PROTACs), are a new modality of chemical tools and potential therapeutics to understand and treat human disease. A required PROTAC component is a ligand binding to an E3 ubiquitin ligase, which is then joined to another ligand binding to a protein to be degraded via the ubiquitin–proteasome system. The advent of nonpeptidic small-molecule E3 ligase ligands revolutionized the field and ushered in the design of drug-like PROTACs with potent and selective degradation activity.; PROTAC-E3 Ligase Ligands | PROTACs | Bifunctional Degrader Molecules; Proteolysis-Targeting Chimeras | PROTAC-E3 Ligase Ligands | PROTACs | Bifunctional Degrader Molecules; PROTAC (Proteolysis-Targeting Chimeras) is a promising approach in drug discovery that involves the use of small molecules to target specific proteins for degradation by the cellular machinery.